Cytek Biosciences (8EQ) Ratios
Cytek Biosciences Ratios
DE:8EQ's free cash flow for Q2 2026 was $-849.00K. For the 2026 fiscal year, DE:8EQ's free cash flow was decreased by $-2.22M and operating cash flow was $1.37M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 |
| Quick Ratio | 4.42 | 5.21 | 5.89 | 8.28 | 12.04 |
| Cash Ratio | 1.17 | 1.46 | 2.98 | 6.05 | 10.99 |
| Solvency Ratio | -0.46 | 0.04 | -0.03 | 0.09 | 0.07 |
| Operating Cash Flow Ratio | -0.06 | 0.38 | 0.09 | -0.25 | 0.14 |
| Short-Term Operating Cash Flow Coverage | -0.74 | 5.45 | 9.35 | -21.09 | 0.00 |
| Net Current Asset Value | $ 272.19M | $ 292.68M | $ 290.67M | $ 360.09M | $ 373.81M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.03 | 0.03 | 0.03 | 0.00 |
| Debt-to-Equity Ratio | 0.07 | 0.04 | 0.04 | 0.04 | 0.00 |
| Debt-to-Capital Ratio | 0.06 | 0.04 | 0.03 | 0.04 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Financial Leverage Ratio | 1.35 | 1.26 | 1.26 | 1.22 | 1.14 |
| Debt Service Coverage Ratio | -7.99 | 0.96 | -0.32 | 3.40 | 3.45 |
| Interest Coverage Ratio | -85.20 | 0.00 | -13.45 | -0.70 | 5.26 |
| Debt to Market Cap | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.19 | 0.13 | 0.12 | 0.15 | 0.01 |
| Net Debt to EBITDA | 3.86 | -17.06 | 34.75 | -29.34 | -40.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 51.84% | 55.43% | 56.69% | 61.56% | 61.86% |
| EBIT Margin | -14.57% | -2.84% | -7.07% | 2.34% | 6.00% |
| EBITDA Margin | -8.63% | 2.39% | -2.28% | 5.79% | 6.97% |
| Operating Profit Margin | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
| Pretax Profit Margin | -14.81% | -2.84% | -8.14% | 0.77% | 4.64% |
| Net Profit Margin | -33.02% | -3.00% | -6.29% | 1.57% | 2.35% |
| Continuous Operations Profit Margin | -33.02% | -3.00% | -6.29% | 1.51% | 2.37% |
| Net Income Per EBT | 222.98% | 105.61% | 77.33% | 204.44% | 50.54% |
| EBT Per EBIT | 73.89% | 27.77% | 56.42% | -69.84% | 64.85% |
| Return on Assets (ROA) | -14.42% | -1.21% | -2.46% | 0.50% | 0.65% |
| Return on Equity (ROE) | -19.47% | -1.52% | -3.09% | 0.61% | 0.74% |
| Return on Capital Employed (ROCE) | -10.52% | -4.75% | -6.35% | -0.38% | 2.13% |
| Return on Invested Capital (ROIC) | -10.28% | -4.66% | -4.88% | -0.38% | 1.09% |
| Return on Tangible Assets | -15.55% | -1.30% | -2.67% | 0.51% | 0.67% |
| Earnings Yield | -10.31% | -0.71% | -0.98% | 0.19% | 0.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.79 | 3.31 | 3.44 | 3.22 | 4.32 |
| Payables Turnover | 15.14 | 16.16 | 27.57 | 13.12 | 16.09 |
| Inventory Turnover | 2.00 | 2.04 | 1.37 | 1.31 | 1.52 |
| Fixed Asset Turnover | 6.87 | 7.13 | 6.60 | 5.95 | 21.87 |
| Asset Turnover | 0.44 | 0.40 | 0.39 | 0.32 | 0.28 |
| Working Capital Turnover Ratio | 0.63 | 0.60 | 0.52 | 0.41 | 0.44 |
| Cash Conversion Cycle | 288.71 | 267.05 | 358.71 | 364.11 | 302.44 |
| Days of Sales Outstanding | 130.66 | 110.32 | 106.13 | 113.20 | 84.53 |
| Days of Inventory Outstanding | 182.17 | 179.31 | 265.83 | 278.71 | 240.59 |
| Days of Payables Outstanding | 24.11 | 22.59 | 13.24 | 27.81 | 22.69 |
| Operating Cycle | 312.82 | 289.63 | 371.95 | 391.92 | 325.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.04 | 0.19 | 0.04 | -0.09 | 0.03 |
| Free Cash Flow Per Share | -0.07 | 0.17 | 0.00 | -0.16 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | -1.15 | 7.20 | 1.09 | -1.24 | 1.06 |
| Capital Expenditure Coverage Ratio | -1.15 | 7.20 | 1.09 | -1.24 | 1.06 |
| Operating Cash Flow Coverage Ratio | -0.20 | 1.49 | 0.37 | -0.68 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.02 | 0.13 | 0.03 | -0.07 | 0.04 |
| Free Cash Flow Yield | -1.36% | 2.58% | 0.04% | -1.61% | 0.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.71 | -140.81 | -101.56 | 533.13 | 727.36 |
| Price-to-Sales (P/S) Ratio | 3.20 | 4.23 | 6.39 | 8.37 | 17.06 |
| Price-to-Book (P/B) Ratio | 1.89 | 2.14 | 3.14 | 3.23 | 5.39 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -73.56 | 38.79 | 2717.58 | -62.15 | 8205.99 |
| Price-to-Operating Cash Flow Ratio | -137.67 | 33.40 | 233.63 | -112.28 | 471.45 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 2.89 | 0.18 | -12.75 | 20.00 |
| Enterprise Value Multiple | -33.23 | 159.91 | -245.15 | 115.34 | 203.81 |
| Enterprise Value | 578.01M | 765.97M | 1.08B | 1.09B | 1.82B |
| EV to EBITDA | -33.23 | 159.91 | -245.15 | 115.34 | 203.81 |
| EV to Sales | 2.87 | 3.82 | 5.60 | 6.67 | 14.21 |
| EV to Free Cash Flow | -65.91 | 35.05 | 2380.22 | -49.54 | 6835.25 |
| EV to Operating Cash Flow | -123.35 | 30.18 | 204.62 | -89.51 | 392.69 |
| Tangible Book Value Per Share | 2.41 | 2.75 | 2.62 | 3.06 | 2.92 |
| Shareholders’ Equity Per Share | 2.68 | 3.03 | 2.91 | 3.16 | 3.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -1.23 | -0.06 | 0.23 | -0.97 | 0.49 |
| Revenue Per Share | 1.58 | 1.53 | 1.43 | 1.22 | 0.96 |
| Net Income Per Share | -0.52 | -0.05 | -0.09 | 0.02 | 0.02 |
| Tax Burden | 2.23 | 1.06 | 0.77 | 2.04 | 0.51 |
| Interest Burden | 1.02 | 1.00 | 1.15 | 0.33 | 0.77 |
| Research & Development to Revenue | 0.18 | 0.20 | 0.23 | 0.21 | 0.19 |
| SG&A to Revenue | 0.54 | 0.46 | 0.23 | 0.21 | 0.16 |
| Stock-Based Compensation to Revenue | 0.12 | 0.13 | 0.11 | 0.10 | 0.05 |
| Income Quality | 0.07 | -4.22 | -0.43 | -4.92 | 1.53 |
Currency in USD